Jade Biosciences, Inc.
Clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.
JBIO | NDAQ
Overview
Corporate Details
- ISIN(s):
- US0080641071
- LEI:
- Country:
- United States of America
- Address:
- 221 CRESCENT ST., 2453 WALTHAM
- Website:
- https://jadebiosciences.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Jade Biosciences, Inc. is a clinical-stage biotechnology company focused on developing a pipeline of potentially best-in-class therapies for autoimmune diseases. The company aims to transform the standard of care for patients in inflammation and immunology. Its programs are built on discovery-stage assets licensed from Paragon Therapeutics. The lead candidate, JADE101, is a therapy designed to inhibit the cytokine APRIL (A PRoliferation-Inducing Ligand) and is being developed for the treatment of immunoglobulin A nephropathy (IgAN).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Jade Biosciences, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Jade Biosciences, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Jade Biosciences, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
